Bristol Myers Squibb’s psoriasis therapy Sotyktu (deucravacitinib) is braced for a downward price adjustment under the cost-effectiveness assessment (CEA) scheme, according to the health ministry’s appraisal results approved on April 24. An oral tyrosine kinase 2 (TYK2) inhibitor, Sotyktu joined…
To read the full story
Related Article
REGULATORY
- PM Takaichi Keeps Cabinet Intact after Lower House Vote
February 18, 2026
- LDP Returnees Set Sights on Social Security, Drug Policy as Special Diet Opens
February 18, 2026
- 10 Firms Win Approval for Bilanoa Generics, 2 Contenders for Fycompa
February 17, 2026
- MHLW to Brand OTC-Like Drug Cost Rule as “Partially Non-Insured Care”
February 17, 2026
- Taiyo Pharma’s Propranolol Designated as Drug for Specific Use
February 17, 2026
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…





